The US biotech funding landscape is entering a critical phase with a unique window of opportunity closing by mid-2026. This article provides essential insights into securing investment, navigating market dynamics, and strategizing for success in this time-sensitive environment.

The 2026 post-quantum cryptography deadline looms for US organizations. This article details the quantum threat, NIST's role, and actionable steps for a smooth migration to quantum-resistant algorithms, emphasizing the urgency to protect sensitive data.